ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients in the Current Era of Immunosuppression

M. Zachariah1, I. Mallawaarachchi2, N. Meeks3, D. Wright1, R. Minawala1, V. Liu1, J. Rolls4, S. Hussein4, C. Jarrin5

1Wayne State University, Detroit, MI, 2Division of Biostatistics, University of Virginia, Charlottsville, VA, 3Wayne State University School of Medicine, Detroit, MI, 4Surgery, Detroit Medical Center, Detroit, MI, 5Infectious Disease, Wayne State University, Detroit, MI

Meeting: 2020 American Transplant Congress

Abstract number: C-007

Keywords: African-American, Antilymphocyte antibodies, Graft survival, Immunosuppression

Session Information

Session Name: Poster Session C: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: It is now common practice in the transplant community to select induction therapy on the basis of perceived immunological risk for acute rejection which commonly includes African american(AA) ethnicity, PRA>20%,and re-transplants. There is little data to support non depleting induction agents in black recipients of renal transplantation

*Methods: Study population is summarized using frequency and percentages..Unadjusted logistic regression models were used to identify the factors associated with graft outcome. Stepwise regression was carried out to obtain final adjusted model. Time to graft loss was modeled using Cox proportional hazard regression. The analysis was done using STATA 15.

*Results: This is a retrospective single center analysis of predominantly African American kidney transplant recipients n=244,followed over mean duration 49±24 mo. (1/2012-12/2018) for Biopsy proven acute rejection(BPAR),viral, bacterial, fungal infection, and graft loss compared between induction agents rATG and IL2RA.All recipients were maintained on calcineurin inhibitor based triple IS.There were 191 first kidney only transplant recipients of whom 39% received induction with rATG and 61% IL2RA .African Americans 91% vs. 9% other.Majority had EPTS > 20 (71%), peak PRA>50% (14%), KDPI >20 in (23%), CIT>24(17%), DCD (18%). African American recipients (n=173). Multivariate analysis, showed no difference in graft survival between induction agents rATG vs. IL2RA (21% vs.18.6%, p=.70). History of first BPAR was similar between groups rATG n=74(39%) and IL2RA n=117(61%) and not significant (16% vs.24%, p=0.27) respectively. when compared with IL2RA, induction with rATG increases the odds of having viral infections adjusted for being on dialysis ≥3 years vs <3 years and re- transplants; OR 2.53 (CI 1.2-5.2, p=0.014), Bacterial infections OR 2.72 ( CI 1.32-5.71, p= 0.006 ), any infection; OR 2.5 ( CI 1.2- 5.2 ,p=0.014). The cause of ESRD, DM or GN were independent risk factors for any infection post-transplant (P=0.005).

*Conclusions: In our single center analysis of predominantly AA renal transplant recipients, type of induction agent used did not demonstrate benefit for graft survival or rejection free survival. There was a significant risk for infection with rATG. Depleting therapy should be balanced against the risks of infection or malignancy in the context of a lack of long‐term data demonstrating a graft survival benefit with type of induction used. Risk stratification based on ethnicity status alone needs to be reconsidered and future research needed to determine the ideal induction agents for specific immunological risk.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Zachariah M, Mallawaarachchi I, Meeks N, Wright D, Minawala R, Liu V, Rolls J, Hussein S, Jarrin C. Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients in the Current Era of Immunosuppression [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/induction-therapy-with-basiliximab-versus-thymoglobulin-in-african-american-kidney-transplant-recipients-in-the-current-era-of-immunosuppression/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences